Shopping Cart

Your shopping cart is currently empty

193 D7

Name: 193 D7
Brand: TargetMol
SKU: T205002
Price: 137 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: JMJD1C-IN-1, 193-D7, 193D7) Copy Product Info

🥰Excellent

Synonyms: JMJD1C-IN-1, 193-D7, 193D7

Catalog No. T205002 Copy Product Info

Purity: 99.41%

🥰Excellent

193 D7 is an orally bioavailable and selective JMJD1C inhibitor with an IC₅₀ of 0.59 μM and a Kd of 1.96 μM. In HTRF assays, it blocks the binding of JMJD1C to the H3K9me2 peptide substrate with an IC₅₀ of 1.47 μM. 193 D7 regulates the fitness of regulatory T cells (Tregs) in the tumor microenvironment via a dual mechanism: it promotes H3K9me2 enrichment to downregulate PD-1 expression and inhibits STAT3 demethylation to enhance STAT3 activation. It exhibits dose-dependent antitumor activity in multiple mouse tumor models, including MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatoma, and CT26 colorectal cancer, and can be used as a tool molecule for selectively targeting intratumoral Tregs in tumor immunity research.

Cas No. 861224-48-8

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$137	-	In Stock
5 mg	$337	-	In Stock
10 mg	$490	-	In Stock
25 mg	$816	-	In Stock
50 mg	$1,130	-	In Stock
100 mg	$1,530	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.41%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	193 D7 is an orally bioavailable and selective JMJD1C inhibitor with an IC₅₀ of 0.59 μM and a Kd of 1.96 μM. In HTRF assays, it blocks the binding of JMJD1C to the H3K9me2 peptide substrate with an IC₅₀ of 1.47 μM. 193 D7 regulates the fitness of regulatory T cells (Tregs) in the tumor microenvironment via a dual mechanism: it promotes H3K9me2 enrichment to downregulate PD-1 expression and inhibits STAT3 demethylation to enhance STAT3 activation. It exhibits dose-dependent antitumor activity in multiple mouse tumor models, including MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatoma, and CT26 colorectal cancer, and can be used as a tool molecule for selectively targeting intratumoral Tregs in tumor immunity research.
Targets & IC50	JMJD1C:0.59 μM, JMJD1C-H3K9me2:1.47 μM (IC50), JMJD1C:1.96 μM (Kd)
In vitro	Methods: The effects of 193 D7 on JMJD1C were determined using HTRF assays and in vitro demethylation assays. Results: 193 D7 inhibited the binding of JMJD1C to the H3K9me2 peptide substrate (IC₅₀ = 1.47 μM) and suppressed the demethylase activity of JMJD1C toward H3K9me2 (IC₅₀ = 0.59 μM) [1].
In vivo	Methods: In tumor-bearing C57BL/6 mouse models, 193 D7 (10–25 mg/kg) was intraperitoneally injected once daily for 2 consecutive weeks, or orally administered at 25 mg/kg once daily for 12 consecutive days. Mice were inoculated with MCA205 fibrosarcoma, MCA205, B16, LLC, and EL4 cells, respectively. Results: 193 D7 exhibited dose-dependent antitumor effects in the above tumor-bearing mice [1].
Synonyms	JMJD1C-IN-1, 193-D7, 193D7

Chemical Properties

Molecular Weight	317.36
Formula	C₁₆H₁₅NO₄S
Cas No.	861224-48-8
Smiles	O=C(O)CC1C(=O)N2C(SCC2)=C(C(=O)C=3C=CC=CC3)C1

Storage & Solubility Information

Storage

Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 8 mg/mL (25.21 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	3.1510 mL	15.7550 mL	31.5100 mL	157.5498 mL
5 mM	0.6302 mL	3.1510 mL	6.3020 mL	31.5100 mL
10 mM	0.3151 mL	1.5755 mL	3.1510 mL	15.7550 mL
20 mM	0.1575 mL	0.7877 mL	1.5755 mL	7.8775 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.